Portions of the brain that activate when people view pictures of objects compared to scrambled images can also be activated by touch alone, confirms a new report published online on May 28th in Current Biology, a Cell Press publication. “That’s the nub of the paper,” said Harriet Allen of the University of Birmingham. “Part of the brain is for object processing irrespective of the sensory input coming in.
Lees meer..

A recent study finds that the antidepressant effects of drugs like Prozac involve both neurogenesis-dependent and -independent mechanisms, a finding that may lead to development of better treatments for depression and anxiety.
Lees meer..

RAJ Devices, the regulatory affairs journal published by Informa and covering the medical technology industry, has published a comprehensive feature on how companies in the US can comply with a much stricter code of ethics that medical technology industry association AdvaMed will launch on 1 July.
Lees meer..

Neurotech Pharmaceuticals, Inc. announced that the Company’s product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments.
Lees meer..

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC).
Lees meer..

Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
Lees meer..

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its Phase 2 clinical trial of picoplatin in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The data demonstrate that picoplatin in combination with docetaxel and prednisone is active as first-line therapy for metastatic CRPC.
Lees meer..

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, provided an update on progress in the company’s clinical program for Cotara(R), a targeted monoclonal antibody-based therapy being tested in a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer.
Lees meer..

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally.
Lees meer..

An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of Alabama at Birmingham (UAB). The new results are from a Phase II clinical trial of AT-101, a pill manufactured from a potent compound in cottonseed that overcomes the abnormal growth patterns of tumor cells.
Lees meer..